KRON: Kronos Bio, Inc. Stock

by  •  • Comments Off on KRON: Kronos Bio, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 61.90
Enterprise Value ($M) -2.43
Book Value ($M) 159.08
Book Value / Share 2.65
Price / Book 0.39
NCAV ($M) 124.58
NCAV / Share 2.07
Price / NCAV 0.50

Profitability (mra)
Return on Invested Capital (ROIC) -0.60
Return on Assets (ROA) -0.39
Return on Equity (ROE) -0.50

Liquidity (mrq)
Quick Ratio 7.24
Current Ratio 7.24

Balance Sheet (mrq) ($M)
Current Assets 178.78
Assets 213.28
Liabilities 54.20
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 6.29
Operating Income -117.22
Net Income -112.67
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -78.58
Cash from Investing 66.37
Cash from Financing 0.57

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-27 13D Bischofberger Norbert W 17.40 79.01
07-07 13G/A BlackRock Inc. 2.40 -56.43

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-21 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO
2023-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PU
2023-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-06 26,320 212,440 12.39
2024-05-03 27,618 299,881 9.21
2024-05-02 22,922 40,187 57.04
2024-05-01 13,766 61,010 22.56

(click for more detail)

Similar Companies
KMDA – Kamada Ltd. KNSA – Kiniksa Pharmaceuticals, Ltd.
KPTI – Karyopharm Therapeutics Inc. KRYS – Krystal Biotech, Inc.
KURA – Kura Oncology, Inc.


Financial data and stock pages provided by
Fintel.io